The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. Shares were up 29% to $8.81 in Monday afternoon ...
In his column “Acrademics,” Alexandre Acra ’26 sheds light on the ins and outs of Stanford and Silicon Valley culture. Dear Acrademics, The world around us seems to be losing rigor and specificity by ...
IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 ...
Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment ...
Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company's share price sank ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results